Proteomics
Antiviral molecules targeting SARS-CoV-2 main protease are potent inhibitors
New compounds targeting the SARS-CoV-2 main protease could be potent inhibitors of the coronavirus. Researchers tested various engineered molecules for antiviral activity in an article published in Science Translational Medicine on August 3.  Discuss
Researchers further define nonstructural protein targets of SARS-CoV-2
The crystal structure of nonstructural protein 16 of SARS-CoV-2, which plays a role in viral RNA capping to mimic host messenger RNA, reveals specific rational design targets that could be used to develop effective therapies against SARS-CoV-2 and other coronaviruses. The research was published in Nature Communications on July 24.  Discuss
Inhibiting SARS-CoV-2 papain-like protease may stop viral spread
Another nonstructural protein, papain-like protease, has been identified as a SARS-CoV-2 therapeutic target with the potential to block viral replication, according to an article published in Nature on July 29.  Discuss
SARS-CoV-2 disguises its own genetic material to facilitate infection
The SARS-CoV-2 virus is able to camouflage itself to promote viral replication, as revealed by structural details of proteins on the surface of the virus. Researchers discovered an enzyme that they believe could be an important target for antiviral drug development, according to a July 14 Nature Communications report.  Discuss
How has SARS-CoV-2 evolved from bat coronavirus?
Structural comparison between a bat coronavirus and SARS-CoV-2 reveals specific characteristics that make the new virus more pathogenic, according to a new article published in Nature Structural and Molecular Biology on July 9.  Discuss
Getting to the heart of SARS-CoV-2 protease; a main drug target
X-ray crystallography performed at room temperature of the main protease of SARS-CoV-2 may be more physiologically relevant than standard low-temperature x-ray structures, according to a June 24 report in Nature Communications.  Discuss
SARS-CoV mAb shown to block SARS-CoV-2
Antibodies from recovered SARS-CoV patients appear to block SARS-CoV-2 infectivity and could help in the development of antiviral treatments or vaccines, according to a new study. The findings were published in Nature on May 18.  Discuss
Scientists explore SARS-CoV-2 main protease as a drug target
A team of researchers report the structure of the main protease of the novel coronavirus and have identified several drugs that show promise in combating the virus, according to an April 9 article published in Nature.  Discuss
Cryo-EM sheds light on ion channel regulation
A long-standing hypothesis about the regulation of ion channels has been confirmed by cryoelectron microscopy (cryo-EM) imaging. The research presented in Nature on March 18 advances the basic understanding of key cellular processes that can be leveraged for a number of therapeutic and research applications.  Discuss
Atomic structures revealed by cryo-EM may lead to new antiviral drugs
Using cryo-electron microscopy (cryo-EM), researchers found unique structures of paramyxoviruses that can lead to a better understanding of viral replication, which in turn can be leveraged to develop improved antiviral drugs. The details were published in the Proceedings of the National Academy of Sciences on February 17.  Discuss
Conferences
ESMO Virtual Congress 2020
September 14-29
Online
BioProcess International West
September 21-25
Online
BioProcess International
September 21-25
Online
ASGCT 2020 Policy Summit
September 23-25
Online
Conferences
ESMO Virtual Congress 2020
September 14-29
Online
BioProcess International West
September 21-25
Online
BioProcess International
September 21-25
Online
ASGCT 2020 Policy Summit
September 23-25
Online
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter